FNC‐producing MSNs loaded with CpG adjuvant and coated with a cancer cell membrane exhibited enhanced accumulation in lymph nodes and immune activation, and greater tumor growth inhibition alone and in combination with the immune checkpoint‐blocking antibody anti‐CTLA‐4 in a melanoma model. Here, CTLA4 is linked to melanoma.